BRCA1 and BRCA2 and the genetics of breast and ovarian cancer - PubMed (original) (raw)
Review
BRCA1 and BRCA2 and the genetics of breast and ovarian cancer
P L Welcsh et al. Hum Mol Genet. 2001 Apr.
Abstract
Germline mutations in the tumor suppressor genes BRCA1 and BRCA2 predispose individuals to breast and ovarian cancers. Progress in determining the function of BRCA1 and BRCA2 suggests that they are involved in two fundamental cellular processes: DNA damage repair and transcriptional regulation. We evaluate current knowledge of BRCA1 and BRCA2 functions to explain why mutations in BRCA1 and BRCA2 lead specifically to breast and ovarian cancer. The BRCA1 and BRCA2 genes contain unusually high densities of repetitive elements. These features of the BRCAs genomic regions contribute to chromosomal instability of these genes. We propose that somatic alterations of BRCA1 and BRCA2 are common and driven by rearrangements between repetitive elements. Inherited and somatic mutations occur in BRCA1 and BRCA2; virtually all somatic mutations are the result of large genomic rearrangements. What are the consequences of such large somatic mutations of BRCA1 and BRCA2 in women with or without inherited mutations? The breast and ovary are estrogen-responsive tissues. Beginning in puberty, the breast epithelium proliferates rapidly in response to fluctuating levels of estrogen. We present a genetic model outlining how BRCA-deficient cells may gain uncontrolled proliferation leading to tumor formation. Central to this model of BRCA-mediated tumorigenesis are estrogen-mediated proliferation of breast and ovarian epithelium and the distinctive genomic context of the BRCA genes.
Similar articles
- A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families.
Machácková E, Foretová L, Navrátilová M, Valík D, Claes K, Messiaen L. Machácková E, et al. Cas Lek Cesk. 2000 Oct 11;139(20):635-7. Cas Lek Cesk. 2000. PMID: 11192759 - BRCA1 and BRCA2 genes: role in hereditary breast and ovarian cancer in Italy.
Santarosa M, Dolcetti R, Magri MD, Crivellari D, Tibiletti MG, Gallo A, Tumolo S, Della Puppa L, Furlan D, Boiocchi M, Viel A. Santarosa M, et al. Int J Cancer. 1999 Sep 24;83(1):5-9. doi: 10.1002/(sici)1097-0215(19990924)83:1<5::aid-ijc2>3.0.co;2-u. Int J Cancer. 1999. PMID: 10449599 - Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations.
Zweemer RP, Shaw PA, Verheijen RM, Ryan A, Berchuck A, Ponder BA, Risch H, McLaughlin JR, Narod SA, Menko FH, Kenemans P, Jacobs IJ. Zweemer RP, et al. J Clin Pathol. 1999 May;52(5):372-5. doi: 10.1136/jcp.52.5.372. J Clin Pathol. 1999. PMID: 10560359 Free PMC article. - Inherited breast cancer: an emerging picture.
Welcsh PL, Schubert EL, King MC. Welcsh PL, et al. Clin Genet. 1998 Dec;54(6):447-58. doi: 10.1111/j.1399-0004.1998.tb03764.x. Clin Genet. 1998. PMID: 9894790 Review. - Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
Casey MJ, Bewtra C, Hoehne LL, Tatpati AD, Lynch HT, Watson P. Casey MJ, et al. Gynecol Oncol. 2000 Sep;78(3 Pt 1):278-87. doi: 10.1006/gyno.2000.5861. Gynecol Oncol. 2000. PMID: 10985881 Review.
Cited by
- Radiotherapy and breast cancer: finally, an lncRNA perspective on radiosensitivity and radioresistance.
Yazarlou F, Martinez I, Lipovich L. Yazarlou F, et al. Front Oncol. 2024 Sep 13;14:1437542. doi: 10.3389/fonc.2024.1437542. eCollection 2024. Front Oncol. 2024. PMID: 39346726 Free PMC article. Review. - Anti-Inflammatory and Anticancer Effects of Anthocyanins in In Vitro and In Vivo Studies.
Kowalczyk T, Muskała M, Merecz-Sadowska A, Sikora J, Picot L, Sitarek P. Kowalczyk T, et al. Antioxidants (Basel). 2024 Sep 22;13(9):1143. doi: 10.3390/antiox13091143. Antioxidants (Basel). 2024. PMID: 39334802 Free PMC article. Review. - Advancements in targeting tumor suppressor genes (p53 and BRCA 1/2) in breast cancer therapy.
Chahat, Nainwal N, Murti Y, Yadav S, Rawat P, Dhiman S, Kumar B. Chahat, et al. Mol Divers. 2024 Aug 17. doi: 10.1007/s11030-024-10964-z. Online ahead of print. Mol Divers. 2024. PMID: 39152355 Review. - Inhibitors against DNA Polymerase I Family of Enzymes: Novel Targets and Opportunities.
Kannan S, Gillespie SW, Picking WL, Picking WD, Lorson CL, Singh K. Kannan S, et al. Biology (Basel). 2024 Mar 22;13(4):204. doi: 10.3390/biology13040204. Biology (Basel). 2024. PMID: 38666816 Free PMC article. Review. - Constitutional BRCA1 and MGMT Methylation Are Significant Risk Factors for Triple-Negative Breast Cancer and High-Grade Serous Ovarian Cancer in Saudi Women.
Al-Moghrabi N, Al-Showimi M, Alqahtani A, Almalik O, Alhusaini H, Almalki G, Saad A, Alsunayi E. Al-Moghrabi N, et al. Int J Mol Sci. 2024 Mar 7;25(6):3108. doi: 10.3390/ijms25063108. Int J Mol Sci. 2024. PMID: 38542081 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous